Use of nitrogen substituted thalidomide analogs for the treatment of macular degenerator
US7153867B2 · kind B2 · utility
16Cited by
16References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 6, 2002 |
| Grant date | Dec 26, 2006 |
| Priority date | — |
| Expiry date | Aug 6, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, nitrogen-substituted thalidomide analogs and di-substituted thalidomide analogs have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.